Report: China Plans to Mass-Produce Four AIDS Drugs

Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.

Report: China Plans to Mass-Produce Four AIDS Drugs

Associated Press (12.27.02) - Friday, December 27, 2002

China plans to make four types of low-cost AIDS drugs, the official Xinhua News Agency reported Thursday, citing Health Minister Zhang Wenkang. The news agency did not say which drugs would be made or whether all four would be mass- produced, but it did say the price would be about one-tenth that of imported drugs, which currently cost 30,000 yuan (US$3,600) per person each year. The average annual income per person in China is $700.

In September, the health ministry denied news reports that it was planning to produce AIDS drugs in violation of foreign patents, but said it wants deeper discounts on the prices of imported drugs. China has begun treating patients with a domestically produced version of AZT, for which patents recently expired. China's health ministry says 10 more Chinese firms have applied for permission to make generic versions of AIDS drugs with expired patents and might be producing them by the end of the year.

The disease has been spread mostly by sharing needles for injecting drugs and unsanitary blood-buying rings. In these, operators reinjected sellers with pooled blood after removing the plasma, making it possible for one HIV-infected person to pass the virus to dozens of others. The government responded by announcing a ban on the plasma trade and said it is creating standard blood banks for donors.

China spent 2.3 billion yuan (US$272 million) last year to establish and upgrade 459 blood banks, Wenkang said. In addition, China has approved 22 million yuan (US$2.7 million) per year in 2002-2004 in subsidies for treatment in the worst- hit areas. Despite the measures, Zhang said the HIV/AIDS fight could be a "long term, arduous and complicated task."
021227
AD022499

Copyright © 2002 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.